Tian Yuan Law Firm

China

IFLR1000 Reviews

Financial and corporate

Formed in 1992, Beijing-based Tian Yuan Law Firm was one of the earliest partnership law firms in China. The firm has since grown to have over 100 partners and more than 500 practitioners across additional offices in Shanghai, Shenzhen, Chengdu, Hong Kong, Hangzhou, Xi'an and Haikou. 

Focusses / specialisms

The firm is best known for its capital markets, M&A and projects work and its funds and private equity practices have been gaining traction of late. It has expertise in the education, healthcare, construction, pharmaceuticals and life sciences, technology and real estate sectors. 

Key clients

Key clients of the firm include Export-Import Bank of China, China Fortune Land Development, Morgan Stanley Asia, Chengdu Ziguang Integrated Circuit Industry Fund, China Yangtze Power, IDG Capital, Sinohydro Corporation and Shougang Group.  

Research period review: 30th edition (2019/2020)

During the research period the firm’s capital markets practice has been very active advising on a number of China, Hong Kong and US IPOs alongside convertible and US dollar bond issues.

In M&A, the firm kept busy with backdoor listings, mergers, investments, corporate restructuring mandates, mixed ownership reform projects, take-privates, and acquisitions in the energy, education, technology, healthcare, chemicals, real estate and electronics industries. 

The projects team has been busy with outbound project and trade finance, while the private equity team has increased visibility assisting clients in various rounds of funding and in funds work. 

The firm bolstered its equity capital markets practice in 2019 with the hires of partners Nan Li from Paul Hastings, Jean Yu from Clifford Chance, Lindsay Gao from Sidley Austin and Charles Wang from Herbert Smith Freehills. The private equity team welcomed in partner Haikun Huang.

Deal highlights: 30th edition (2019/2020)

-Chengdu Ziguang Integrated Circuit Industry Fund

-China Yangtze Power $3.6 billion acquisition of 83.6% stake in Luz Del Sur

-Haier Biomedical SSE STAR Market IPO

-Hansoh Pharmaceutical HKSE IPO

-Huohua Siwei $85 million series D financing 

-NetEase Youdao NYSE IPO

-Sino Biopharmaceutical €750 million zero-interest convertible bond issue

-Sinohydro Corporation $2 billion Ghana infrastructure construction package-deal EPC and financing